Laninamivir (brand name Inavir® in Japan) is a long-acting antiviral drug used for the treatment and prevention of influenza A and B infections, approved and available only in Japan. It’s a neuraminidase inhibitor, given as a single-dose dry powder inhaler, effectively shortening illness duration, especially for children, and working against some oseltamivir-resistant strains, making it useful for both seasonal flu and pandemic preparedness. Its therapeutic use is listed as antivirals. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include laninamivirum and LANI. Its PubChem CID is 502272.
Laninamivir
| CAS No | 203120-17-6 |
|---|---|
| Molecular Formula | C13H22N4O7 |
| Molecular Weight | 346.34 g/mol |
| Synonyms | (2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-2,3-dihydroxy-1-methoxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Laninamivir (brand name Inavir® in Japan) is a long-acting antiviral drug used for the treatment and prevention of influenza A and B infections, approved and available only in Japan.
The listed CAS number is 203120-17-6.
The listed molecular formula is C13H22N4O7.
The listed molecular weight is 346.34 g/mol.
(2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-2,3-dihydroxy-1-methoxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid.
The source lists laninamivirum and LANI.